FindTrial
Sign In

The application value of Nanopore Sequencing Technology in rapid etiological identification of patients with febrile neutropenia: a prospective and observational clinical study

The application value of Nanopore Sequencing Technology in rapid etiological identification of patients with febrile neutropenia: a prospective and observational clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066088
Enrollment
Unknown
Registered
2022-11-23
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia

Interventions

Gold Standard:Blood culture
Index test:the Nanopore Sequencing Technology
the metagenomic Next Generation Sequencing (mNGS)

Sponsors

The Affiliated Drum Tower Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limitation; 2. Patients with malignant hematologic diseases and febrile neutropenia with high risk factors according to the guideline; 3. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Lack of treatment compliance; 2. Be considered inappropriate by researchers.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;accuracy;—

Secondary

MeasureTime frame
time efficiency;consistency;—

Countries

China

Contacts

Public ContactXu Yueyi

The Affiliated Drum Tower Hospital of Nanjing University Medical School

may6204@163.com15851811336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026